127700 20241125101158.0 doi 10.37201/req/007.2023 sideral 134649 ART-2023-134649 eng García-Fernández, Sergio Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020 2023 Access copy available to the general public Unrestricted Objectives. To determine susceptibility to the novel β-lactam/β-lactamase inhibitor combination imipenem/relebactam in clinical isolates recovered from intra-abdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream (BSI) infections in the SMART (Study for Monitoring Antimicrobial Resistance Trends) study in SPAIN during 2016 – 2020. Methods. Broth microdilution MICs for imipenem/relebactam and comparators were determined by a central laboratory against isolates of Enterobacterales and Pseudomonas aeruginosa. MICs were interpreted using EUCAST-2021 breakpoints. Results. In total, 5,210 Enterobacterales and 1,418 P. aeruginosa clinical isolates were analyzed. Imipenem/relebactam inhibited 98.8% of Enterobacterales. Distinguishing by source of infection susceptibility was 99.1% in BSI, 99.2% in IAI, 97.9% in RTI, and 99.2% in UTI. Of intensive care unit isolates (ICU) 97.4% were susceptible and of non-ICU isolates 99.2% were susceptible. In Enterobacterales, activity against Class A, Class B and Class D carbapenemases was 96.2%, 15.4% and 73.2%, respectively. In P. aeruginosa, imipenem/relebactam was active in 92.2% of isolates. By source of infection it was 94.8% in BSI, 92.9% in IAI, 91.7% in RTI, and 93.1% in UTI. An 88.7% of ICU isolates and 93.6% of non-ICU isolates were susceptible to imipenem/relebactam. Imipenem/relebactam remained active against P. aeruginosa ceftazidime-resistant (76.3%), cefepime-resistant (73.6%), imipenem-resistant (71.5%) and piperacillin-resistant (78.7%) isolates. Of all multidrug-resistant or difficult-to-treat resistance P. aeruginosa isolates, 75.1% and 46.2%, respectively, were susceptible to imipenem/relebactam. Conclusions. Imipenem/relebactam showed high rates of susceptibility in Enterobacterales and P. aeruginosa isolates from different sources of infection as well as depending on patients’ location (ICU or non-ICU scenarios). info:eu-repo/semantics/openAccess by-nc http://creativecommons.org/licenses/by-nc/3.0/es/ 1.9 2023 PHARMACOLOGY & PHARMACY 231 / 354 = 0.653 2023 Q3 T2 MICROBIOLOGY 130 / 161 = 0.807 2023 Q4 T3 0.399 2023 Medicine (miscellaneous) 2023 Q3 Pharmacology 2023 Q3 Microbiology (medical) 2023 Q3 2.9 2023 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Calvo, Jorge Cercenado, Emilia Suárez-Barrenechea, Ana Isabel Fernández-Billón, María Castillo, Francisco Javier Gálvez-Benítez, Lydia Tubau, Fe Figueroa Cerón, Ruth Esther Hernández-Cabezas, Alicia González Romo, Fernando Fariñas, María Carmen Gómez, María Díaz-Regañón, Jazmín Cantón, Rafael 36, 3 (2023), 302-309 Rev. esp. quimioter. Revista española de quimioterapia 0214-3429 592380 http://zaguan.unizar.es/record/127700/files/texto_completo.pdf Versión publicada 3192100 http://zaguan.unizar.es/record/127700/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:127700 articulos driver 2024-11-22-12:10:36 ARTICLE